entertainment -WSS

entertainment

author：comprehensive 2025-09-29 10:31:34 - browse：18898

Red blood cells flow in an artery biotech — coverage from STAT — Adobe

PHILADELPHIA — An investigational drug aimed at preventing strokes significantly reduced the risk of bleeding compared with a commonly used blood thinner for stroke prevention, showing potential to be a safer alternative for patients.

Among patients with atrial fibrillation, an abnormal heart rhythm that increases the risk of stroke, abelacimab, developed by Anthos Therapeutics, cut the overall risk of bleeding by 67% compared to rivaroxaban, the blood thinner sold as Xarelto by Janssen Pharmaceuticals.

The treatment, injected monthly, also reduced the risk of major bleeding events by 74% and gastrointestinal bleeding by 93%, according to Phase 2 results presented here Sunday at the American Heart Association conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Prime Medicine says its gene editing passes test in monkeys

leisure time

Wikipedia

WSS

Gene therapy’s promise and the high cost of hope

How neuroscience research could help beat back brain cancer

All of Us, NIH's precision medicine initiative, gets a big boost

Medicare must police algorithms in Medicare Advantage, Dems say

Profiling embryos to choose those with higher IQs is almost a reality

Brain injuries and the importance of a second opinion

hotspot

entertainment

focus

In Memoriam: Notable people who died in 2023

Profiling embryos to choose those with higher IQs is almost a reality

Continuity nursing helped my family in our darkest PICU moments

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

United colonoscopy coverage change 'may cost lives,' doctors say

Live blog: Hearing on CRISPR

Guidelines to prevent youth baseball injuries need more muscle

Medicare proceeds with plan to claw back hospital funds

Bright Health sells Medicare Advantage business to Molina

Sarepta Duchenne therapy fails to meet primary endpoint in trial

entertainment

All of Us, NIH's precision medicine initiative, gets a big boost

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

A preacher's new calling: Diversifying neuroscience research

Brain injuries and the importance of a second opinion

Explaining an after

How to convince healthy people to buy insurance

leisure time

leisure time

Wikipedia

entertainment